While hot melt extrusion was developed in the 1930s and initially used in the plastics and food sector, the pharmaceutical industry has now firmly embraced this technology platform in its manufacturing as a way of solving formulation challenges.

Advantages of the approach include the ability to use a wide range of excipients and the ease with which process analytical technology can be incorporated.

In this podcast, we speak to Bruce Frank at Lubrizol Life Science Health about how HME has developed as a proven technology for bioavailability enhancement of poorly soluble active pharmaceutical ingredients and drug eluting implants and devices, and how it stacks up against other formulation options in terms of cost and scalability in order to deliver high quality, commercialised pharmaceutical products.